AZRX vs. APRE, LEXX, SPRB, DARE, NRXP, ACST, FBRX, SLGL, QLI, and DRRX
Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include Aprea Therapeutics (APRE), Lexaria Bioscience (LEXX), Spruce Biosciences (SPRB), Daré Bioscience (DARE), NRx Pharmaceuticals (NRXP), Acasti Pharma (ACST), Forte Biosciences (FBRX), Sol-Gel Technologies (SLGL), Qilian International Holding Group (QLI), and DURECT (DRRX). These companies are all part of the "medical" sector.
Aprea Therapeutics (NASDAQ:APRE) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment.
Aprea Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.
AzurRx BioPharma received 180 more outperform votes than Aprea Therapeutics when rated by MarketBeat users. Likewise, 74.26% of users gave AzurRx BioPharma an outperform vote while only 51.72% of users gave Aprea Therapeutics an outperform vote.
AzurRx BioPharma's return on equity of -65.58% beat Aprea Therapeutics' return on equity.
34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are owned by institutional investors. 20.9% of Aprea Therapeutics shares are owned by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, AzurRx BioPharma's average media sentiment score of 0.00 equaled Aprea Therapeutics'average media sentiment score.
Aprea Therapeutics has higher revenue and earnings than AzurRx BioPharma. Aprea Therapeutics is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.
Aprea Therapeutics currently has a consensus target price of $15.50, suggesting a potential upside of 189.72%. Given AzurRx BioPharma's higher probable upside, equities research analysts clearly believe Aprea Therapeutics is more favorable than AzurRx BioPharma.
Summary
Aprea Therapeutics beats AzurRx BioPharma on 9 of the 13 factors compared between the two stocks.
Get AzurRx BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AZRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AzurRx BioPharma Competitors List
Related Companies and Tools
